Huashanpai

Huashanpai (Shanghai) Biotechnology is a clinical-stage biopharmaceutical company focused on the development of recombinant protein vaccines and therapeutic antibodies for infectious diseases. Spun out from the Infectious Diseases Department of Shanghai Huashan Hospital, the company leverages the clinical expertise of renowned experts like Dr. Zhang Wenhong to address unmet needs in public health. Its core technology involves a proprietary protein engineering platform used to design high-purity antigens for vaccines targeting COVID-19 and Herpes Zoster (shingles). Huashanpai is also active in developing rapid diagnostic solutions for emerging pathogens, such as the Monkeypox virus. Backed by the Shanghai Biomedical Fund, the company is a key participant in China's efforts to build a robust infectious disease R&D ecosystem.